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Abstract
In rodents, activation of L-type calcium channels with ± BayK 8644 causes an unusual behavioral
syndrome that includes dystonia and self-biting. Prior studies have linked both of these behaviors to
dysfunction of dopaminergic transmission in the striatum. The current studies were designed to
further elucidate the relationship between ± BayK 8644 and dopaminergic transmission in the
expression of the behavioral syndrome. The drug does not appear to release presynaptic dopamine
stores, since microdialysis of the striatum revealed dopamine release was unaltered by ± BayK 8644.
In addition, the behaviors were preserved or even exaggerated in mice or rats with virtually complete
dopamine depletion. On the other hand, pretreatment of mice with D3 or D1/5 dopamine receptor
antagonists attenuated the behavioral effects of ± BayK 8644, while pretreatment with D2 or D4
antagonists had no effect. In D3 receptor knockout mice, ± BayK 8644 elicited both dystonia and
self-biting, but these behaviors were less severe than in matched controls. In D1 receptor knockout
mice, behavioral responses to ± BayK 8644 appeared exaggerated. These results argue that the
behavioral effects of ± BayK 8644 are not mediated by a presynaptic influence. Instead, the behaviors
appear to result from a postsynaptic activation of the drug, which does not require but can be modified
by D3 or D1/5 receptors.
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Introduction
In mice, administration of the dihydropyridine analog ± BayK 8644 causes a motor syndrome
characteristic of dystonia with slow, stiff and twisting movements [Jinnah et al., 2000]. In
young mice, it also causes stereotypical self-biting (SB) [Jinnah et al., 1999b]. The mechanisms
by which this drug causes these unusual behaviors remain unknown, but several lines of
evidence have indicated they reflect the drug's ability to activate L-type voltage-regulated
calcium channels (CaV 1.2 and CaV 1.3). The behavioral manifestations emerge after treatment
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with the (−) BayK 8644 enantiomer that is known to activate these channels, but not after the
inactive (+) BayK 8644 enantiomer. The behavioral syndrome also can be reproduced with a
structurally dissimilar nondihydropyridine activator of L-type calcium channels, FPL 64176.
The behaviors provoked with ± BayK 8644 can be prevented by pretreatment with L-type
calcium channel blockers such as nifedipine, nimodipine, or nitrendipine. Finally, the
behavioral syndrome is absent from knockout mice carrying a mutation of the cacna1d gene,
which results in null activity of Cav 1.2 channels [Sinnegger-Brauns et al., 2004]. Taken
together, these observations provide strong evidence that dystonia and SB with ± BayK 8644
emerge after activation of these L-type calcium channels.
There are several reasons to suspect the behavioral syndrome results from activation of L-type
channels associated with the striatal dopamine pathways. The influence of ± BayK 8644 on
regional brain activity was recently delineated by mapping the induction of the immediate-
early gene c-fos [Jinnah et al., 2004]. Despite the nearly ubiquitous expression of L-type
calcium channels in the brain, these functional mapping studies revealed a heterogeneous effect
on regional brain activity, with the most prominent changes in the striatum. In addition, co-
administration of drugs that augment dopaminergic transmission, such as amphetamine or
GBR-12909, exaggerate stereotypical SB in response to ± BayK 8644 [Kasim and Jinnah,
2003]. On the other hand, pretreatment with drugs that deplete dopamine stores, such as
reserpine or tetrabenazine, attenuate SB [Kasim and Jinnah, 2003].
An influence of ± BayK 8644 on striatal dopaminergic systems is consistent with studies from
other animal and human studies that have linked dystonia with dysfunction of striatal
dopaminergic pathways [Berardelli et al., 1998; Perlmutter and Mink, 2004]. For example,
dystonia is a prominent feature of dopa-responsive dystonia, which results from inherited
deficiency of dopamine synthesis [Nygaard et al., 1991; Ichinose et al., 1994]. Dystonia also
occurs in degenerative disorders affecting dopaminergic pathways, such as Parkinson disease
[Nausieda et al., 1980; Jankovic, 2005a]. Finally, dopamine replacement therapies and
dopamine receptor antagonists both can cause dystonia under certain circumstances [Jankovic,
2005b; Skidmore and Reich, 2005]. The mechanism by which a defect of dopaminergic
transmission might cause dystonia is unknown but it is hypothesized to result from an
imbalance or poor coordination of opposing stimulatory and inhibitory motor output from the
striatum [Berardelli et al., 1998; Mink, 2003].
Other studies also have linked self-injurious behaviors with abnormalities of dopaminergic
transmission [Visser et al., 2000; Schroeder et al., 2001]. SB and self-injurious biting (SIB)
occur after large doses or repeated administration of drugs that promote dopamine release, such
as amphetamine [Brien et al., 1977; Mueller et al., 1982; Lara-Lemus et al., 1997],
methamphetamine [Kita et al., 2000; Shishido et al., 2000; Halladay et al., 2003], or pemoline
[Mueller and Nyhan, 1982; Mueller et al., 1986; King et al., 1995; Cromwell et al., 1999;
Turner et al., 1999]. They also emerge after repeated administration of high doses of the
dopamine reuptake blocker, GBR-12909 [Sivam, 1995; Loupe et al., 2002]. Finally, they are
seen consistently after dopamine agonist treatment in rats that had 6-hydroxydopamine
(6OHDA) lesions of dopamine pathways in the neonatal period [Breese et al., 1984a, b,
1990, 1994; Moy et al., 1997]. The mechanisms leading to SIB are hypothesized to result from
excessive presynaptic release of the transmitter and/or overstimulation of supersensitive
postsynaptic receptors [Jinnah et al., 1990; Visser et al., 2000; Schroeder et al., 2001].
The mechanisms by which the L-type channels might interact with dopaminergic pathways to
cause dystonia and SB remain uncertain. Two prior studies have suggested that activation of
L-type calcium channels with ± BayK 8644 stimulates a massive release of presynaptic
dopamine stores [Watanabe et al., 1998; Okita et al., 2000]. Other studies have shown ± BayK
8644 to stimulate dopamine release from striatal synpatosomes, slices of striatum in vitro, and
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cultured midbrain dopamine neurons [Nordstrom et al., 1986; Woodward and Leslie, 1986;
Woodward et al., 1988; Chaudieu et al., 1992]. The L-type calcium channel also interacts with
postsynaptic striatal dopamine receptors to exert a number of physiological effects. For
example, D1 dopamine receptor agonists increase while D2 dopamine receptor agonists
decrease calcium currents carried by L-type calcium channels in subpopulations of striatal
medium spiny neurons [Surmeier et al., 1995; Hernandez-Lopez et al., 2000]. The ability of
dopamine to augment glutamate transmission via NMDA receptors in striatal medium spiny
neurons also depends partly on an L-type calcium current [Florez-Hernandez et al., 2002].
Additionally, D2 receptor-mediated suppression of calcium oscillations in mid-brain dopamine
neurons and D5 receptor-mediated burst firing of subthalamic neurons both are mediated by
an L-type calcium channel [Yasumoto et al., 2004]. These findings suggest that the behavioral
syndrome associated with ± BayK 8644 could reflect a presynaptic or postsynaptic mechanism.
The purpose of the present studies was to further delineate the role of dopaminergic systems
in the expression of the behavioral syndrome provoked by ± BayK 8644.
Methods
Drugs
The ± BayK 8644, GR-103691, L-741,626, L-745,870, SCH-23390, SKF-83566, U-99194,
and 6OHDA were obtained from Sigma-RBI (St. Louis, Mo., USA). The ± BayK 8644 was
prepared as previously described [Jinnah et al. 1999b, 2000]. Briefly, stock solutions of 10 mg/
ml were first dissolved in a mixture containing equal parts of ethanol and Tween-80 and stored
in amber vials at 4°C for up to 1 month. The stock was freshly diluted with distilled water
immediately before it was used. The remaining drugs were freshly dissolved in distilled water
or saline. All drugs were injected in a total volume of 10 ml/kg.
Normal and Mutant Mice
Normal C57BL/6J mice were obtained from the Jackson Laboratories (Bar Harbor, Me., USA)
and bred and maintained at Johns Hopkins University in groups of 2–12. The dopamine-
deficient (DD) mice were bred and maintained at the University of Washington in Seattle, as
previously described [Kim et al., 2000; Chartoff et al., 2001]. These mice were generated by
genetic deletion of the endogenous tyrosine hydroxylase (Th) gene, with a subsequent targeting
of the Th gene to the dopamine beta-hydroxylase (Dbh) locus. These Th−/−;DbhTh/+ mice (DD
mice) exhibit severe dopamine loss without norepineprhine or epinephrine loss. Mice carrying
a mutation in the D3 dopamine receptor (D3 knockouts) were obtained from Jackson
Laboratories and bred at Johns Hopkins University along with strain-matched controls. Mice
carrying a mutation in the D1 dopamine receptor (D1 knockouts) were kindly supplied by
Richard Mailman (University of North Carolina, Chapel Hill, N.C.) and bred along with strain-
matched controls. Both male and female mice were evaluated after weaning at 4–5 weeks of
age.
All animals had free access to food and water at all times. All procedures were conducted in
accordance with guidelines described by the National Institutes of Health Guide for Care and
Use of Laboratory Animals and the Animal Care and Use Committee of the appropriate
institution.
Microdialysis
Microdialysis of the striatum was performed to determine if ± BayK 8644 induced dopamine
release in mice. Concentric microdialysis probes were prepared as previously described [Page
et al., 2003]. Briefly, a fused silica tube with 149 μm OD and 70 μm ID (Polymicro
Technologies, Phoenix, Ariz., USA) was inserted into PE20 tubing (Clay Adams, Becton
Dickinson, Franklin Lakes, N.J., USA), leaving ~1 cm of silica exposed. Dialysis tubing with
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a molecular weight limit of 18,000 kDa (Spectrum Laboratories, Rancho Dominguez, Calif.,
USA) was placed over the end of the silica and into the PE10 tubing and secured with epoxy.
The open end of the dialysis membrane was sealed with an epoxy plug, leaving an active area
of ~2 mm for solute exchange across the membrane. Recovery rates for dopamine were
determined for each probe before use and averaged 16.04 ± 0.98%.
Eight mice were anesthetized with 2,2,2-tribromoethanol and positioned in a stereotaxic
apparatus equipped with a mouse adapter (Stoelting, Wood Dale, Ill., USA). The microdialysis
probe was implanted in the striatum (+0.6 AP, +1.7 ML, 4.5 DV) according to an atlas of the
mouse brain [Paxinos and Franklin, 2001]. A drop of Superglue (Ross Inc., Columbus, Ohio,
USA) was applied to the skull and the probe was secured with dental cement (Lang Dental
Manufacturing Co., Wheeling, Ill., USA). After surgery, the probe was connected to a
microinjection pump (Harvard Apparatus, Holliston, Mass., USA) with a liquid swivel (Instech
Laboratories, Plymouth Meeting, Pa., USA) and perfused continuously with artificial
cerebrospinal fluid (147 mM NaCl, 3.5 mM KCl, 1.2 mM CaCl2 , 1.2 mM MgCl2 , 1 mM
NaH2PO4 , 25 mM NaHCO3 , pH 7.0–7.4) at a flow rate of 1.5 μl/min. Microdialysis samples
were collected 14–16 h after surgery using 0.65-ml polypropylene tubes containing 5 μl of the
artificial cerebrospinal fluid supplemented with 1.75 μM ascorbic acid as a preservative. The
sampling interval was 20 min. The first sample was discarded and the next 4 samples were
collected as baseline. Further samples were collected after sequential treatment with vehicle,
4 mg/kg ± BayK 8644, and 4 mg/kg amphetamine. All samples were immediately frozen and
stored for HPLC analysis of monoamines. Data were corrected for probe recovery rates and
analyzed using a paired t test to compare drug treatments with baseline. The location of the
probe was verified by histological examination of the brain and by verifying the expected
increase in dopamine after amphetamine.
± BayK 8644 Behaviors in Mice
To assess the role of presynaptic dopamine stores, behavioral responses to ± BayK 8644 were
evaluated in DD mutant mice and in mice with partial 6OHDA lesions of the dopamine
pathways. The 6OHDA lesions were performed as previously described [Visser et al., 2002].
In brief, 20 mice between 4–5 weeks of age were treated subcutaneously with 20 mg/kg
desipramine to block uptake of the toxin into noradrenergic neurons. Approximately 30–40
min later, they were anesthetized with inhaled methoxyflurane. The nape of the neck was
shaved, and a 5-mm incision made at the occiput. A 27-gauge needle was inserted 2–3 mm and
used to deliver 75 μg of 6OHDA freshly dissolved in 0.9% saline with 0.01% ascorbic acid
into the 4th ventricle. Another group of 20 mice, treated in parallel with subcutaneous
desipramine and intracisternal vehicle, served as controls. Wounds were treated with Tritop
analgesic and antiseptic ointment, and closed with cyanoacrylate tissue adhesive (Veterinary
Laboratory Products, Phoenix, Ariz., USA).
A 2-week recovery period was allowed before behavioral testing with ± BayK 8644. The
animals usually recovered normal ingestive behaviors within 24 h, and they appeared
behaviorally normal within 1–2 weeks. One control animal was excluded from the final analysis
because of failure to resume normal motor behaviors.
Dystonia was defined as abnormal motor behavior characterized by torsional movements
leading to odd postures and was evaluated as previously described [Jinnah et al., 2000].
Animals were placed singly in clear plastic chambers and observed for 1 min every 10 min for
an hour. The severity of the motor disorder was rated on a 4-point scale at each recording
interval, and all 6 scores were averaged to yield a single score for each animal. Results were
compared via two-way ANOVA, with post-hoc Tukey t tests where appropriate.
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SB and SIB were also evaluated as previously described [Kasim et al., 2002; Kasim and Jinnah,
2003]. SB was defined as biting any portion of the body without tissue injury, while SIB was
defined as biting that resulted in tissue injury. SIB was terminated whenever it occurred by
immediate anesthetization with methoxyflurane followed by 10 mg/kg subcutaneous
nifedipine to prevent unnecessary pain or suffering.
Several pilot studies were conducted to determine the best methods for scoring and analyzing
SB and SIB, taking into consideration the requirement for immediate termination of SIB when
it occurred. As a result of the frequent precipitous development of SIB, it was not feasible to
employ rating scales for the degree of tissue injury analogous to those used in other studies
where the behavior evolves more slowly [Kies and Devine, 2004]. The latency to onset of the
behaviors provided too much variation, and the duration of the behaviors could not be used
because of the requirement for termination of SIB as soon as it occurred [Kasim and Jinnah,
2003]. The most direct approach involved determining the total number of animals displaying
either behavior but suffered two limitations. First, recording an all-or-none score obscured
subtle differences in the severity of the behaviors. Second, the resultant data required analysis
with relatively insensitive nonparametric statistics for categorical measures. This type of
analysis increases the risk of missing important differences.
Ultimately, a two-step process was used. For SB, a time sampling procedure was used to
estimate the percentage of time the behavior occurred during the test session. In brief, animals
were monitored for 1 min every 10 min for an hour for SB. The 6 observation periods were
then averaged to provide an estimate of the percentage of time SB occurred [Kasim et al.,
2002; Kasim and Jinnah, 2003]. Dose-response profiles were compared by two-way ANOVA
with post-hoc Tukey t tests where appropriate.
The time sampling method could not be used for SIB, since this behavior had to be stopped as
soon as it occurred. SIB was directly recorded as a categorical variable and analyzed using the
χ2 statistic for nonparametric measures. The combination of percent time for SB and the
frequency of progression to SIB provided a close quantitative approximation for both frequency
and severity of the behavioral manifestations.
At the conclusion of behavioral testing, the extent of 6OHDA lesions was confirmed by
measuring dopamine and its metabolites in dissected caudoputamen from all animals [Visser
et al., 2002]. Monoamines were measured by HPLC (ESA, Chelmsford, Mass., USA) with an
array of electrochemical detectors set at 150, 250, 450, and 550 mV [Jinnah et al., 1999a]. The
samples were injected directly onto a C18 reverse-phase MD-150 column and eluted over a
24-min period at a flow rate of 0.6 ml/min with an isocratic solvent consisting of 1.7 mM 1-
octanesulfonic acid sodium, 25 μM EDTA, 0.01% triethylamine, and 8% acetonitrile in 75
mM sodium phosphate buffer, pH 2.9. Dopamine and its metabolites were identified and
quantified by means of simultaneous standards. Results for each metabolite were compared
using Student's t test.
± BayK 8644 Behaviors in Rats
To further address the potential contributions of presynaptic dopamine stores, behavioral
responses to ± BayK 8644 were evaluated in rats with near-total 6OHDA lesions of dopamine
systems during early development. Pregnant Sprague-Dawley rats were obtained from Harlan
(Indianapolis, Ind., USA) and maintained at the University of North Carolina with free access
to food and water. 6OHDA lesions were performed as previously described [Papadeas et al.,
2004]. Briefly, male and female neonatal rats at 3–5 days of age were first pre-treated with 20
mg/kg desipramine subcutaneously to block uptake of the toxin into noradrenergic neurons.
Approximately 60 min later they were anesthetized with ether and given intracisternal
injections of 100 μg of 6OHDA (free base) freshly dissolved in 10 μl of saline with 0.01%
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ascorbic acid as a preservative. This treatment results in >95% loss of dopamine and its axons
in the striatum [Papadeas et al., 2004]. Sham-lesioned controls were treated similarly except
the 6OHDA was omitted from the vehicle. One vehicle-treated control died after surgery and
was not further evaluated.
The pups were weaned at 30 days of age, and behavior testing was performed at 35 days of
age. Behavioral observations in rats were conducted using a modification of the methods used
in mice. The rats were observed for 5 min every 15 min for a total of 80 min. During each
observation period, continuous recordings were made of the time animals engaged in SB. The
time spent SB per period was averaged across all rats. The severity of dystonia was scored only
during the first minute of each observation period.
Drug-Induced Motor Activity
To assess the roles of postsynaptic dopamine receptors, ± BayK 8644 behaviors were evaluated
after pretreating mice with one of several receptor antagonists. To verify that the drugs were
not causing nonspecific sedation that might interfere with behavioral assessments, suppression
of locomotor activity was investigated first with automated activity chambers [Jinnah et al.,
1992]. The chambers consisted of 20 × 40 cm Plexiglas boxes with 4 infrared beams spanning
the short axis and 8 infrared beams spanning the long axis (San Diego Instruments,
www.sd-inst.com). Unless otherwise noted, mice were placed singly in the chambers 15–20
min after receiving a test drug during their dark phase when they are normally most active.




Dopamine in striatal microdialysates was measured to determine if ± BayK 8644 induced
striatal dopamine release. No abnormal behaviors were observed in any of 8 mice after
treatment with vehicle. After 4 mg/kg ± BayK 8644, all displayed dystonia and SB, with 6
progressing to SIB. However, there was no apparent increase in dopamine or its metabolites
in the microdialysis samples after injection of ± BayK 8644 (fig. 1).
The location of the probe within the striatum was verified histologically in each case (fig. 2).
To verify that the microdialysis probes were capable of measuring an increase in dopamine
release, microdialysis samples were also collected for 60 min from half of the animals after
treatment with 4 mg/kg amphetamine following ± BayK 8644. In each case, amphetamine
provoked a significant increase in dopamine (fig. 1). These results provide evidence against
the proposal that the behavioral consequences of ± BayK 8644 are due to a massive dopamine
release in the striatum.
6OHDA-Treated Mice
The behavioral responses of mice with partial 6OHDA-induced lesions of brain dopamine
systems were assessed to further clarify the role of dopamine. The rationale was that if ± BayK
8644 caused its behavioral effects by provoking dopamine release, then the 6OHDA-lesioned
mice should exhibit attenuated responses because they have lower dopamine stores. The goal
was to assess behavioral responses in mice with partial 6OHDA lesions, because more severe
lesions cause impairments that might interfere with the interpretation of responses provoked
by ± BayK 8644.
Mice were given intracisternal 6OHDA at 4–5 weeks of age, and behavioral testing with ±
BayK 8644 was conducted after recovery from the lesions at 6–8 weeks of age. Because SB
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and particularly SIB are more prominent in weanling mice in comparison to adults [Jinnah et
al., 1999b], the allowance of a 2-week recovery period led to relatively low rates of SIB in this
experiment (table 1). In comparison with mice treated in parallel with vehicle, however, the
6OHDA had no apparent effect on the ability of ± BayK 8644 to cause either SB or SIB (table
1). On the other hand, 6OHDA slightly worsened motor disability scores.
Neurochemical assessment of the mice following behavioral testing revealed that 6OHDA
treatment was successful in reducing striatal dopamine by an average of 58% compared to the
vehicle-treated controls (table 2). All dopamine metabolites were similarly reduced by
6OHDA. These results are consistent with those from microdialysis in arguing against the
proposal that the behavioral effects of ± BayK 8644 result from dopamine release.
DD Mice
The behavioral responses of DD mutant mice were assessed to determine if more severe
dopamine depletions might be required to attenuate behavioral responses to ± BayK 8644.
These mice exhibit almost complete loss of striatal dopamine with profound hypoactivity, and
they require daily L-DOPA supplements for survival. The DD mice were challenged with ±
BayK 8644 approximately 24 h after their last maintenance dose of L-DOPA, a time when
residual dopamine stores are <5% of normal and the animals typically demonstrate profound
hypoactivity [Kim et al., 2000; Chartoff et al., 2001].
Despite their profound hypoactivity at the time of behavior testing with ± BayK 8644, the DD
mice demonstrated significantly more SB in comparison with controls matched for age and
sex (table 3). There was also a trend towards an increase in SIB that did not reach statistical
significance. The DD mice also exhibited significantly higher motor disability scores than the
control animals. Consistent with prior studies, neurochemical analyses of whole brains from
the DD mice confirmed severe loss of brain dopamine with only 2% of normal levels (table
4). These results are consistent with those of the 6OHDA experiment in suggesting that release
of presynaptic dopamine is not required for the behavioral effects of ± BayK 8644.
6OHDA Rats
The behaviors induced by ± BayK 8644 were also evaluated in rats with neurotoxin-induced
depletion of striatal dopamine. Neonatal treatment with 6OHDA was chosen for two reasons.
First, severe impairments of spontaneous motor behavior like those of the DD mice are absent
in adult rats even with doses of 6OHDA that eliminate >95% of residual striatal dopamine,
provided that the lesions are made within the first few days after birth [Moy et al., 1997].
Residual endogenous dopamine is necessary for maintaining the relatively normal motor
behavior, but the animals are behaviorally resistant to amphetamine and other dopamine-
releasing agents [Castenada et al., 1990]. Second, treated animals exhibit a well-characterized
response that includes multiple stereotypic behaviors including SIB when repeatedly
challenged as adults with L-DOPA or dopamine agonists [Breese et al., 1985].
Pilot studies in control animals indicated that rats were more sensitive and showed a very
narrow dose-response profile to ± BayK 8644 in comparison with mice. The test dose range
was adjusted to reflect this species difference. The 6OHDA-lesioned rats exhibited
significantly more SB and dystonia in comparison with the sham-lesioned group (table 5). SIB
occurred in the 6OHDA-lesioned animals, but was absent from the sham-lesioned controls.
These results are consistent with those observed in mice with dopamine depletion and provide
further support that presynaptic dopamine is not essential for the behavioral effects of ± BayK
8644.
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Locomotor Responses to Dopamine Receptor Antagonists
The preserved behavioral responses of dopamine-depleted animals to ± BayK 8644 suggest
that the behavioral responses are not dependent upon presynaptic dopamine release. Instead,
the sometimes enhanced sensitivity to the drug suggests the possibility of postsynaptic
supersensitivity. To assess the role of postsynaptic dopamine receptors, the behavioral
responses to ± BayK 8644 were evaluated in mice pretreated with one of several antagonists
selective for individual dopamine receptor sub-types. Because many of these antagonists cause
sedation or hypoactivity that might interfere with interpreting behavioral responses to ± BayK
8644, the motor suppressive effects of the drugs were first evaluated for different doses of each
antagonist, using the dose ranges delineated in prior studies [Bristow et al., 1997, 1998; Audinot
et al., 1998; LaHoste et al., 2000].
Consistent with prior studies, the D1/5 antagonists SCH-23390 and SKF-83566 both caused a
dose-dependent suppression of motor behavior (fig. 3). Suppression of motor behavior by the
D2 antagonist L-741,626 or the D3 antagonist GR-103691 was noted only at high doses (fig.
3). The D3 antagonist U-99194 increased motor behavior, while the D4 antagonist L-745,870
had no significant effect on motor behavior (fig. 3). None of the drugs caused SB, SIB, other
oral stereotypies, or dystonic motor behavior.
Dopamine Antagonists Modify Behavioral Responses to ± BayK 8644
The dose-response profiles for motor behavior were used to guide selection of the maximum
doses of the antagonists while avoiding marked nonspecific suppression of motor behavior.
Pretreatment with 0.1 mg/kg SCH-23390 significantly reduced both SB and SIB in response
to ± BayK 8644 (fig. 4), with no significant influence on motor disability scores. A higher
pretreatment dose of 1 mg/kg further suppressed SB and SIB while increasing motor disability
scores (not shown). Pretreatment with 0.1 mg/kg SKF-83566 significantly reduced SB and
increased motor disability scores (fig. 4). There was a trend for reduced SIB that was not
statistically significant. A higher pretreatment dose of 1 mg/kg significantly suppressed SB
and SIB, and increased motor disability scores (not shown). These results provide evidence for
involvement of D1 and/or D5 receptors in the behavioral actions of ± BayK 8644.
Pharmacological discrimination of which of these receptors might be most relevant is not
possible because of the lack of subtype-specific antagonists.
Pretreatments with 1 mg/kg GR-103691 significantly reduced SB while slightly increasing
motor disability scores in response to ± BayK 8644 (fig. 4). Pretreatment with 10 mg/kg
U-99194 also reduced SB but had no influence on motor disability scores. There was a trend
for reduced SIB with both D3 antagonists, but this did not reach statistical significance. These
results provide indirect evidence for involvement of D3 dopamine receptors in some of the
behavioral actions of ± BayK 8644.
Pretreatment with 1 mg/kg of the D2 antagonist, L-741,626, had no significant influence on
any of the behavioral consequences of ± BayK 8644. Pretreatment with 1 mg/kg of the D4
antagonist, L-745,870, also had no significant effect. These results argue that D2 and D4
receptors do not play a role in the behavioral actions of ± BayK 8644.
Behavioral Responses of Dopamine Receptor Knockout Mice to ± BayK 8644
To further assess the role of D3 dopamine receptors, behavioral responses to ± BayK 8644
were evaluated in D3 receptor knockout mice. At baseline the D3 knockouts appeared
physically and behaviorally normal as previously reported [Accili et al., 1996]. The behavioral
responses of the D3 knockouts to ± BayK 8644 were preserved but less pronounced than those
of control mice matched for age, sex, and background genetic strain (table 6). SB and dystonia
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were both less prominent in the D3 knockouts. There was a trend for reduced SIB that did not
reach statistical significance.
Similar studies of the role of D1 receptors were conducted by assessing behavioral responses
of D1 receptor knockout mice to ± BayK 8644. The weanling D1 knock-outs showed obvious
signs of delayed physical development that could be attenuated with dietary supplements as
previously described [Holmes et al., 2004]. However, the delay in physical development could
not be eliminated during the ages required for behavioral testing with ± BayK 8644. The
behavioral responses of the D1 knock-outs to ± BayK 8644 were preserved and often
exaggerated. Quantitative assessments were not attempted, because the delay in physical
development confounded the behavioral responses to ± BayK 8644, which are known to be
critically dependent upon developmental status [Jinnah et al., 1999b].
Discussion
Activation of L-type calcium channels with ± BayK 8644 causes dystonic motor behavior and
SIB in young mice and rats. In prior studies, these behaviors have been linked with
abnormalities of dopaminergic transmission in the striatum [Kasim and Jinnah, 2003]. The
current studies confirm that dopaminergic pathways are involved in the expression of dystonia
and self-injurious behaviors induced by ± BayK 8644. However, the influence of ± BayK 8644
on dopaminergic transmission is not likely to be mediated at the presynaptic level, since
microdialysis of the striatum provided no evidence for dopamine release after ± BayK 8644
and behavioral responses were preserved or even exaggerated in animals after near-total
dopamine depletion. Instead, it seems more likely that the influence of ± BayK 8644 is mediated
by postsynaptic L-type channels.
It is interesting to note that acute depletion of dopamine with tetrabenazine or reserpine
suppressed SB and SIB [Kasim and Jinnah, 2003], while more chronic depletion of dopamine
after 6OHDA lesions had no effect on SB and SIB (table 2). The differing results cannot be
explained by the degree of dopamine loss or species variations, since both studies employed
mice and reached 50–60% depletion of total dopamine stores. More severe chronic dopamine
depletions in the DD mutant mice and the neonatal 6OHDA-lesioned rats actually led to
exaggerated SB and SIB in response to ± BayK 8644 (tables 3, 5). These observations suggest
that adaptive changes to severe chronic dopamine depletion, such as dopamine receptor
supersensitivity, may increase susceptibility to SB and SIB. Indeed, dopamine receptor
supersensitivity is thought to be a key feature of SB and SIB that occurs after dopamine agonist
treatment in rats with neonatal 6OHDA lesions [Moy et al., 1997].
Results of the current studies contradict those of two prior studies, which demonstrated >100-
fold increase in rat striatal dopamine microdialysates after ± BayK 8644 [Watanabe et al.,
1998; Okita et al., 2000]. The discrepancy could reflect the different species used, the location
of the microdialysis probe within the striatum, or the mode of drug delivery. Most notably, the
current micro-dialysis studies were performed after subcutaneous drug delivery, while the prior
study was conducted after direct intracerebral administration of the drug dissolved in
dimethylsulfoxide. Regardless of the reasons for the differing results, the current studies
showed no increase in striatal dopamine release under conditions where the behavioral effects
were directly observed, demonstrating that the behavioral responses can be dissociated from
any potential striatal dopamine release.
For the behaviors provoked by ± BayK 8644, the D3 dopamine receptor is implicated by the
converging results showing that D3 dopamine receptor antagonists attenuate behavioral
responses in normal mice, and by observations that D3 dopamine receptor knockout mice are
less sensitive to the drug than normal controls. The D1 or D5 dopamine receptors are implicated
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by similar pharmacological studies using antagonists selective for D1/5 receptors. Though
antagonists capable of discriminating these receptors are not available, the D1 receptor is more
likely to be involved in these responses than the D5 receptor. The D1 receptor is heavily
expressed in the striatum, it functionally interacts with L-type calcium channels, and it has
been linked with a number of dopamine-related behavior [Hernandez-Lopez et al., 1997;
Florez-Hernandez et al., 2002; Holmes et al., 2004]. Unfortunately, a specific role for D1
receptors could not be confirmed in D1 dopamine receptor knockouts because of their
developmental delay.
Although the available results imply a role for D3 or D1/5 receptors in the expression of dystonia
and SB after ± BayK 8644, the observation that these behaviors persisted under experimental
conditions that reduce dopaminergic transmission via D3 or D1/5 receptors argues that neither
receptor is required for expression of the behaviors. It remains possible that these different
classes of receptors exhibit some redundancy of functions, requiring elimination of both to
block behavioral responses to ± BayK 8644. It is equally plausible that these receptors modify
behavioral responses to ± BayK 8644 via an L-type calcium channel, but that the receptors can
be bypassed by direct activation of the channel.
These results allow for a novel interpretation of the role of abnormal striatal dopamine
transmission in the expression of dystonia and self-injurious behaviors. The basic striatal
microcircuit consists of excitatory glutamatergic inputs on the heads of spines of medium spiny
neurons, which constitute 95% of striatal neurons and the chief striatal output mechanism [for
review, see Cepeda and Levine, 1998]. Dopaminergic inputs to the striatum modulate the
efficacy of corticostriatal signaling via synapses onto the necks of the spines. The action of
dopamine on individual medium spiny neurons is complex, as it can both stimulate or inhibit
their activity. Dopamine enhances glutamateric excitation of medium spiny neurons via a
mechanism that involves D1 receptor stimulation and enhanced calcium conduction via L-type
calcium channels [Galarraga et al., 1997; Hernandez-Lopez et al., 1997; Cepeda and Levine,
1998]. Dopamine also inhibits glutamatergic excitation via a mechanism that involves D2
receptor stimulation and reduced L-type calcium conductances [Hernandez-Lopez et al.,
2000; Yasumoto et al., 2004]. Normally, D1 and D2 receptors subserve separate and opposing
striatal output pathways, acting in concert to facilitate intended behaviors while suppressing
extraneous behaviors. The simultaneous and direct activation of L-type calcium channels in
both pathways with ± BayK 8644 may cause a disruption of the normal balance of excitatory
and inhibitory output thought to underlie dystonic motor behavior. The excessive presynaptic
release of dopamine and/or overstimulation of super-sensitive postsynaptic receptors thought
to underlie self-injurious behaviors similarly might be replicated by direct activation of ± BayK
8644-sensitive L-type calcium channels normally influenced by dopaminergic stimulation. In
essence, the ability of dopamine to influence the expression of dystonia and SIB after ± BayK
8644 and perhaps other situations is indirect, being related to its role as a neuromodulator of
corticostriatal glutamatergic signaling.
While further studies will be required to evaluate the proposed roles of striatal dopamine and
glutamate pathways in the expression of dystonia or SIB, the postulated role of L-type calcium
channels in causing these behaviors leads to the prediction that inhibitors of these channels
may be useful for these disorders.
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Striatal microdialysates after ± BayK 8644 or amphetamine. Average dopamine values ± SEM
are shown for 4–8 mice per sampling interval. Drug treatments were given once subcutaneously
at the start of each epoch, depicted by shades of gray. A paired t test was used to compare an
average of the first 40 min after treatments (when the most prominent behavioral abnormalities
were occurring) with average 40 min of baseline. There were no significant differences between
baseline, vehicle, and ± BayK 8644 treatment. However, there was a significant difference
between baseline and amphetamine treatment (p < 0.001).
Kasim et al. Page 15














Location of microdialysis probes. The target was AP 0.6, ML 1.7, and DV 4.5 according to a
mouse atlas [Paxinos and Franklin, 2001]. The active zone of all probes fell within the stippled
region shown. CPU = Caudoputamen, CTX = cortex, ac = anterior commissure, LV = lateral
ventricle.
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Motor activity after pretreatment with dopamine receptor antagonists. All animals were naïve
to the behavior apparatus and to the test drug. They were placed in the activity chambers without
habituation 10–15 min following drug delivery, and total activity was recorded for 2 h. Results
show average values ± SEM from 8 mice per drug dose.
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± BayK 8644 behaviors after pretreatment with dopamine receptor antagonists. Drug-naïve
animals were given a single pretreatment dose of the dopamine receptor antagonist indicated,
or matched vehicle. In all cases the vehicle-treated control mice are shown as gray bars and
the antagonist-pretreated mice are shown as black bars. Approximately 10 min later they were
then challenged with one of three test doses of ± BayK 8644. Behavioral responses to ± BayK
8644 after the antagonist were compared to the simultaneously pretreated vehicle group as
described in the methods. The results of the statistical comparisons are indicated within each
panel.
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Table 1
± BayK 8644 in 6OHDA-lesioned mice
Treatment group SB SIB Dystonia
Control
 2 mg/kg 0.9 ± 0.9 0/19 1.5 ± 0.1
 4 mg/kg 29.0 ± 7.6 1/19 1.7 ± 0.1
 8 mg/kg 53.5 ± 7.2 2/19 2.0 ± 0.1
6OHDA lesioned
 2 mg/kg 0.8 ± 0.9 0/20 1.7 ± 0.1
 4 mg/kg 24.2 ± 5.5 0/20 1.8 ± 0.1
 8 mg/kg 53.3 ± 5.5 1/20 2.3 ± 0.1*
Results for SB reflect average percentage of time the behavior was observed ± SEM for 19 mice in the vehicle-treated group and 20 mice in the
6OHDA-treated group. These results were analyzed by two-way ANOVA with 6OHDA treatment and ± BayK 8644 dose as main factors. This analysis
revealed a significant effect for ± BayK 8644 dose (F2, 111 = 51.5, p < 0.0001). There was no significant effect for 6OHDA treatment (F1, 111 =
0.2, p = 0.7) and with no significant interaction (F2,111 = 0.1, p = 0.9). Results for SIB reflect number of animals displaying the behavior compared
with the total number of animals observed. These data were not subject to statistical analysis because of the small number of responders. Results for
dystonia reflect average motor scores and were analyzed by two-way ANOVA with 6OHDA treatment and ± BayK 8644 dose as main factors. This
analysis revealed a significant effect for 6OHDA treatment (F1, 111 = 6.4, p = 0.013) and ± BayK 8644 dose (F2, 111 = 16.2, p < 0.0001), with no
significant interaction (F2, 111 = 0.6, p = 0.6).
*
Significant difference from corresponding control group at each dose by post-hoc Tukey t test (p < 0.05).
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Table 2
Striatal monoamines in 6OHDA-lesioned mice
Treatment group Dopamine DOPAC HVA 3MT
Control (n = 19) 142.0 ± 6.6 7.3 ± 0.3 13.1 ± 0.6 8.8 ± 0.4
6OHDA lesioned (n = 20) 60.0 ± 5.4* 3.7 ± 0.2* 6.8 ± 0.3* 5.9 ± 0.3*
Results depict average values ± SEM in ng/mg protein.
*
A 2-tailed t test revealed a significant difference (p < 0.01) for each metabolite.













Kasim et al. Page 21
Table 3
± BayK 8644 in DD mutant mice
Treatment group SB SIB Dystonia
Control
 2 mg/kg 4.2 ± 2.9 0/8 1.2 ± 0.1
 4 mg/kg 20.8 ± 6.5 0/8 1.9 ± 0.1
 8 mg/kg 43.8 ± 15.8 2/8 2.3 ± 0.2
DD mutants
 2 mg/kg 4.2 ± 2.9 0/8 2.2 ± 0.1*
 4 mg/kg 39.6 ± 10.6 2/8 3.0 ± 0.2*
 8 mg/kg 70.8 ± 12.9* 4/8 3.4 ± 0.1*
Results for SB reflect average percentage of time the behavior was observed ± SEM for 8 mice per group. These results were analyzed by two-way
ANOVA with genotype and ± BayK 8644 dose as main factors. This analysis revealed a significant effect for both genotype (F1, 42 = 4.1, p < 0.05)
and dose (F2, 42 = 16.5, p < 0.001), with no significant interaction (F2, 42 = 1.1, p > 0.10). Results for SIB reflect number of animals displaying the
behavior compared with the total number of animals observed. These data were analyzed by the χ2 statistic, and revealed no significant differences
between the genotypes (χ2 = 1.2, p = 0.27). Results for dystonia reflect average motor scores and were analyzed by two-way ANOVA with genotype
and ± BayK 8644 dose as main factors. This analysis revealed a significant effect for both genotype (F1, 42 = 75.8, p < 0.001) and dose (F2, 42 =
31.4, p < 0.001), with no significant interaction (F2, 42 = 0.01, p > 0.10).
Asterisks show significant differences from corresponding control group at each dose by post-hoc Tukey t tests (p < 0.05).
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Table 4
Whole brain monoamines in DD mutant mice
Treatment group Dopamine DOPAC HVA 3MT
Control (n = 10) 63.4 ± 2.4 6.4 ± 0.9 13.8 ± 1.8 11.1 ± 1.6
DD mutants (n = 7) 1.6 ± 0.2* ND 1.1 ± 0.1 ND
Results depict average values ± SEM in ng/mg protein.
*
For dopamine, a 2-tailed t test revealed p < 0.0001. Average HVA values were also low in the DD mice, but a formal statistical comparison was not
conducted because 2 of 7 mice had undetectable levels (<1 ng/mg protein). DOPAC and 3MT were not detectable in the DD mice.
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Table 5
± BayK 8644 in 6OHDA-treated rats
Treatment group SB SIB Dystonia
Sham lesioned
 1 mg/kg 0.0 ± 0.0 0/5 0.9 ± 0.2
 2 mg/kg 0.0 ± 0.0 0/10 1.5 ± 0.3
 3 mg/kg 3.3±1.8 0/10 3.5±0.2
6OHDA lesioned
 1 mg/kg 0.0 ± 0.0 0/5 1.8 ± 0.3*
 2 mg/kg 39.8 ± 11.5* 2/15 3.0 ± 0.3*
 3 mg/kg 112.4 ± 22.8* 3/8 3.7 ± 0.2
Results for SB reflect average number of seconds ± SEM for each observation period. These results were analyzed by two-way ANOVA with lesion
and ± BayK 8644 dose as main factors. This analysis revealed a significant effect for lesion (F1, 222 = 16.8, p < 0.0001) and dose (F2, 221 = 8.3, p
< 0.0005), as well as a significant interaction of dose and lesion (F2, 218 = 7.2, p < 0.001).
Asterisks show significant differences from sham-lesioned rats at each dose as determined by Fisher's PLSD (p < 0.05). Results for SIB reflect number
of animals displaying the behavior compared with the total number of animals observed. These data were analyzed by the χ2 statistic, which revealed
a significant difference between the treatment groups (χ2 = 4.9, p = 0.026). Results for dystonia reflect average time-weighted motor scores and were
analyzed by two-way ANOVA with lesion and ± BayK 8644 dose as main factors. This analysis revealed a significant effect for lesion (F2, 113 =
16.6, p < 0.0001) and dose (F1, 112 = 33.8, p < 0.0001) as well as a significant interaction (F2, 109 = 3.3, p < 0.05).
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Table 6
± BayK 8644 in D3 knockout mice
Treatment group SB SIB Dystonia
Control
 2 mg/kg 0 ± 0 0/10 1.7 ± 0.1
 4 mg/kg 68.3 ± 11.8 5/10 2.0 ± 0.1
 8 mg/kg 98.3 ± 1.8 8/10 3.0 ± 0.2
D3 KO
 2 mg/kg 2.1 ± 2.2 0/8 1.2 ± 0.2*
 4 mg/kg 41.7 ± 13.0* 1/8 1.8 ± 0.2
 8 mg/kg 89.6 ± 7.5 5/8 3.0 ± 0.1
Results for SB reflect average percentage of time the behavior was observed ± SEM for 10 mice for each control group and 8 mice for each D3
knockout group. These results were analyzed by ANOVA with genotype and ± BayK 8644 dose as main factors. The effect of genotype was borderline
(F1, 48 = 3.4, p = 0.07). The effect of ± BayK 8644 dose was significant (F1 48 = 81.0, p < 0.001) but the interaction between genotype and ± BayK
8644 was not (F2, 48 = 2.0, p = 0.2). Results for SIB reflect number of animals displaying the behavior. These data were analyzed by the χ2 statistic,
which revealed no significant difference between the genotypes (χ2 = 2.0, p = 0.16). Results for dystonia reflect average motor scores and were
analyzed by ANOVA with genotype and ± BayK 8644 dose as main factors. There were significant effects for both genotype (F1, 48 = 6.7, p < 0.02)
and ± BayK 8644 dose (F2, 48 = 111.7, p < 0.001), with a significant interaction for genotype X ± BayK 8644 dose (F2, 48 = 3.3, p < 0.05).
*
Significant differences between genotypes at corresponding ± BayK 8644 doses by post-hoc Tukey t tests (p < 0.05).
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